共 16 条
[1]
Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report[J] Henry Lik-Yuen Chan;Alex Thompson;Michelle Martinot-Peignoux;Teerha Piratvisuth;Markus Cornberg;Maurizia Rossana Brunetto;Hans L. Tillmann;Jia-Horng Kao;Ji-Dong Jia;Heiner Wedemeyer;Stephen Locarnini;Harry L.A. Janssen;Patrick Marcellin Journal of Hepatology 2011,
[2]
Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa[J] Erik H.C.J. Buster;Bettina E. Hansen;George K.K. Lau;Teerha Piratvisuth;Stefan Zeuzem;Ewout W. Steyerberg;Harry L.A. Janssen Gastroenterology 2009,
[3]
2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B[J] Yun–Fan Liaw;Edward Gane;Nancy Leung;Stefan Zeuzem;Yuming Wang;Ching Lung Lai;E. Jenny Heathcote;Michael Manns;Natalie Bzowej;Junqi Niu;Steven–Huy Han;Seong Gyu Hwang;Yilmaz Cakaloglu;Myron J. Tong;George Papatheodoridis;Yagang Chen;Nathaniel A. Brown;Efsevia Albanis;Karin Galil;Nikolai V. Naoumov Gastroenterology 2009,
[4]
Baseline characteristics and early on-treatment response predict the outcomes of 2<ce:hsp sp="0.25"/>years of telbivudine treatment of chronic hepatitis B[J] Stefan Zeuzem;Edward Gane;Yun-Fan Liaw;Seng G. Lim;Adrian DiBisceglie;Maria Buti;Anuchit Chutaputti;Jens Rasenack;Jinlin Hou;Christopher O’Brien;Tuan T. Nguyen;Jidong Jia;Thierry Poynard;Bruce Belanger;Weibin Bao;Nikolai V. Naoumov Journal of Hepatology 2009,
[5]
911 PROLONGED EFFICACY AND SAFETY OF 3 YEARS OF CONTINUOUS TELBIVUDINE TREATMENT IN POOLED DATA FROM GLOBE AND 015 STUDIES IN CHRONIC HEPATITIS B PATIENTS[J] C.-W. Hsu;Y.-C. Chen;Y.-F. Liaw;E. Gane;M. Manns;S. Zeuzem;Y. Wang;C.L. Lai;J. Hou;N. Leung;N. Bzowej;J. Niu;J. Jia;S.G. Hwang;Y. Cakaloglu;H. Ren;G. Papatheodoridis;Y. Chen;W. Bao;P. Lopez Journal of Hepatology 2009,
[6]
EASL Clinical Practice Guidelines: Management of chronic hepatitis B[J] European Association for the Study of the Liver Journal of Hepatology 2009,
[7]
Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients[J] Rami Moucari;Vincent Mackiewicz;Olivier Lada;Marie‐Pierre Ripault;Corinne Castelnau;Michelle Martinot‐Peignoux;Agnes Dauvergne;Tarik Asselah;Nathalie Boyer;Pierre Bedossa;Dominique Valla;Michel Vidaud;Marie‐Hélène Nicolas‐Chanoine;Patrick Marcellin Hepatology 2009,
[8]
Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B[J] Maurizia Rossana Brunetto;Francesco Moriconi;Ferruccio Bonino;George K. K. Lau;Patrizia Farci;Cihan Yurdaydin;Teerha Piratvisuth;Kangxian Luo;Yuming Wang;Stephanos Hadziyannis;Eva Wolf;Philip McCloud;Richard Batrla;Patrick Marcellin Hepatology 2009,
[9]
Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B[J] Emmet B. Keeffe;Stefan Zeuzem;Raymond S. Koff;Douglas T. Dieterich;Rafael Esteban–Mur;Edward J. Gane;Ira M. Jacobson;Seng G. Lim;Nikolai Naoumov;Patrick Marcellin;Teerha Piratvisuth;Fabien Zoulim Clinical Gastroenterology and Hepatology 2007,
[10]
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years[J] Stephanos J. Hadziyannis;Nicolaos C. Tassopoulos;E. Jenny Heathcote;Ting–Tsung Chang;George Kitis;Mario Rizzetto;Patrick Marcellin;Seng Gee Lim;Zachary Goodman;Jia Ma;Carol L. Brosgart;Katyna Borroto–Esoda;Sarah Arterburn;Steven L. Chuck Gastroenterology 2006,